Study summary · research use only
Editorial: vasoactive intestinal peptide (vip): historic perspective and future potential
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This editorial reviews the history and future potential of vasoactive intestinal peptide (VIP), noting that studies since the late 1970s have described VIP's role in the mammalian immune system. It states that VIP has an inhibitory effect on the production and action of various inflammatory mediators and that many studies have examined VIP's therapeutic potential in animal models of human disease. The editorial discusses VIP's effects on immune cell function, its therapeutic potential in inflammatory diseases in humans, and introduces related research areas covered by contributing authors in the special issue.
Abstract
Numerous studies, since the late 1970s, have highlighted the role of vasoactive intestinal peptide (VIP) in the immune system of mammals. Importantly, these studies have show that VIP has an inhibitory effect on the production and action of many different inflammatory mediators and many studies have now shown the therapeutic potential of VIP in animal models of human disease. This review will briefly discuss the effects of VIP on immune cell function and discuss the therapeutic potential for VIP in inflammatory diseases of humans. The review will also introduce some areas of research which are discussed by contributing authors within this special edition of EMIDDT.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.